Lv41
468 积分 2025-02-06 加入
Recent advances and future strategies in first-line treatment of ES-SCLC
10分钟前
待确认
Complement activation in cancer: Effects on tumor-associated myeloid cells and immunosuppression
1个月前
已完结
B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome
1个月前
已完结
Whole-brain irradiation with simultaneous integrated boost by helical tomotherapy for multiple brain metastases: dosimetric and clinical analyses
1个月前
已完结
Efficacy, safety, and exploratory biomarker analysis of envafolimab plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer: a prospective, single-arm, phase II trial
1个月前
已完结
The next generation of immunotherapies for lung cancers
1个月前
已完结
Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive‐stage small cell lung cancer (ES‐SCLC): ECOG‐ACRIN EA5161
1个月前
已完结
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
1个月前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
1个月前
已完结
Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial
1个月前
已完结
皖公网安备34019202002308
